Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Chordia TherapeuticsTSE:190A -2.53%11 Market Cap is 円5,791.66 Mil as of Jul. 19, 2026. GuruFocus rates TSE:190A with a GF Score™ of 11/100. The stock has 1 warning sign investors should review. Among 1,424 Biotechnology companies, Chordia Therapeutics ranks worse than 67.98% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Chordia Therapeutics's share price for the quarter that ended in Feb. 2026 was 円167. Chordia Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Feb. 2026 was 73.73 Mil. Therefore, Chordia Therapeutics's market cap for the quarter that ended in Feb. 2026 was 円12,313.08 Mil.
Chordia Therapeutics's quarterly market cap
declined
from Feb. 2025 (円16,833.32 Mil) to Aug. 2025 (円12,418.02 Mil) and
declined
from Aug. 2025 (円12,418.02 Mil) to Feb. 2026 (円12,313.08 Mil).
Chordia Therapeutics's annual market cap
increased
from Aug. 2023 (円0.00 Mil) to Aug. 2024 (円52,789.62 Mil) but then
declined
from Aug. 2024 (円52,789.62 Mil) to Aug. 2025 (円12,418.02 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Chordia Therapeutics's Enterprise Value for Today is 円3,285.08 Mil.
Chordia Therapeutics (TSE:190A) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Chordia Therapeutics Market Cap Related Terms
Chordia Therapeutics Market Cap Historical Data
* Premium members only.
The historical data trend for Chordia Therapeutics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:190A vs VRTX, REGN, ALNY: Market Cap Comparison
For the Biotechnology subindustry, Chordia Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chordia Therapeutics Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Chordia Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Chordia Therapeutics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Chordia Therapeutics's Market Cap for the fiscal year that ended in Aug. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chordia Therapeutics (TSE:190A) has a Market Cap of 円5,791.66 Mil as of Jul. 19, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Chordia Therapeutics and its competitors. According to the industry distribution chart, Chordia Therapeutics ranks #968 out of 1424 companies in the Biotechnology industry, placing it in the top 68%.
Is Chordia Therapeutics' Market Cap too high?
Chordia Therapeutics' current Market Cap is 円5,791.66 Mil. Based on the distribution chart, Chordia Therapeutics ranks #968 out of 1424 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Chordia Therapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Chordia Therapeutics' Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Chordia Therapeutics ranks #968 out of 1424 companies for Market Cap. This places Chordia Therapeutics in the lower half of its industry. The industry median Market Cap is 112.84. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 112.84, based on 1,424 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Chordia Therapeutics and its competitors. For the Biotechnology industry, the median Market Cap is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chordia Therapeutics's current Market Cap is 円5,791.66 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chordia Therapeutics stock overvalued right now?
Chordia Therapeutics (TSE:190A) has a current Market Cap of 円5,791.66 Mil. The current Market Cap is 円5,791.66 Mil. Chordia Therapeutics' overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Chordia Therapeutics (TSE:190A), the current Market Cap is 円5,791.66 Mil as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Chordia Therapeutics Inc is a bio-venture company specializing in cancer research and development. Its mission is to deliver first-in-class cancer drugs to patients. It is a clinical-stage biotech company engaged in researching and developing novel therapies for cancers with high unmet medical needs.
11GF Score
Get the complete analysis for TSE:190A
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:190A has been successfully added to your 
